HANSOH PHARMA (03692) announced that on May 9, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC), HS-20093 for injection, has been approved by China's National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy designation program. The intended indication is for unresectable locally advanced or metastatic esophageal squamous cell carcinoma in patients who have failed prior first-line treatment containing platinum-based chemotherapy and immune checkpoint inhibitor (ICI) therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments